<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Pandey S</submitter><funding>NCI NIH HHS</funding><pagination>102336</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11905928</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>5(12)</volume><pubmed_abstract>Small molecules that can reduce the neurotoxic beta-amyloid (Aβ) aggregates in the brain provide a potential treatment for Alzheimer disease (AD). Most screening methods for small-molecule hits focus on the overall Aβ aggregations without a specific target, such as the very first association step (i.e., nucleation) &lt;i>en route&lt;/i> to the Aβ oligomers. Located in the middle of a full-length Aβ peptide, Aβ&lt;sub>19-20&lt;/sub> (diphenylalanine or FF) nucleates the neurotoxic Aβ oligomer formation. Here, we innovate a single-molecule screen method in optical tweezers by targeting the nucleation process in Aβ aggregation, namely FF-dimerization. With a 121-compound National Institutes of Health (NIH) library, we identify 12 inhibitors and 8 stimulants that can inhibit/promote Aβ&lt;sub>19-20&lt;/sub> dim</pubmed_abstract><journal>Cell reports. Physical science</journal><pubmed_title>&amp;lt;i&amp;gt;De novo&amp;lt;/i&amp;gt; design of a mechano-pharmaceutical screening platform against formation of individual beta-amyloid oligomers.</pubmed_title><pmcid>PMC11905928</pmcid><funding_grant_id>R01 CA252827</funding_grant_id><pubmed_authors>Zhang G</pubmed_authors><pubmed_authors>Pokhrel P</pubmed_authors><pubmed_authors>Harris P</pubmed_authors><pubmed_authors>Sharma G</pubmed_authors><pubmed_authors>Mao H</pubmed_authors><pubmed_authors>Hao Y</pubmed_authors><pubmed_authors>Jeon BT</pubmed_authors><pubmed_authors>Pandey S</pubmed_authors><pubmed_authors>Christensen NJ</pubmed_authors><pubmed_authors>Zhang Z</pubmed_authors><pubmed_authors>Danielsen MB</pubmed_authors><pubmed_authors>Lou C</pubmed_authors><pubmed_authors>Leng Y</pubmed_authors><pubmed_authors>Xiang Y</pubmed_authors><pubmed_authors>Song S</pubmed_authors><pubmed_authors>Sorensen KK</pubmed_authors><pubmed_authors>Kim MH</pubmed_authors><pubmed_authors>Cunningham R</pubmed_authors></additional><is_claimable>false</is_claimable><name>&amp;lt;i&amp;gt;De novo&amp;lt;/i&amp;gt; design of a mechano-pharmaceutical screening platform against formation of individual beta-amyloid oligomers.</name><description>Small molecules that can reduce the neurotoxic beta-amyloid (Aβ) aggregates in the brain provide a potential treatment for Alzheimer disease (AD). Most screening methods for small-molecule hits focus on the overall Aβ aggregations without a specific target, such as the very first association step (i.e., nucleation) &lt;i>en route&lt;/i> to the Aβ oligomers. Located in the middle of a full-length Aβ peptide, Aβ&lt;sub>19-20&lt;/sub> (diphenylalanine or FF) nucleates the neurotoxic Aβ oligomer formation. Here, we innovate a single-molecule screen method in optical tweezers by targeting the nucleation process in Aβ aggregation, namely FF-dimerization. With a 121-compound National Institutes of Health (NIH) library, we identify 12 inhibitors and 8 stimulants that can inhibit/promote Aβ&lt;sub>19-20&lt;/sub> dim</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Dec</publication><modification>2025-04-26T03:23:41.458Z</modification><creation>2025-04-06T10:51:16.939Z</creation></dates><accession>S-EPMC11905928</accession><cross_references><pubmed>40083584</pubmed><doi>10.1016/j.xcrp.2024.102336</doi></cross_references></HashMap>